Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL

Nurix Therapeutics, Inc.

2024-Q2 EPS reported -$1.47 revenue$28,677,000

Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).
Cash and marketable securities $452.5M as of May 31, 2024, up from $254.3M after $188.7M public offering.
NX-5948 Phase 1a/b data: ORR 69.2% in heavily pretreated CLL patients; plans for pivotal trial in 2025.
Appointed Paula O'Connor as CMO and Pasit Phiasivongsa as CTO to lead clinical and CMC operations.
Entered into Amendment No.1 to equity distribution agreement allowing up to $150M ATM offerings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.